Technical Analysis for LENZ - LENZ Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 15.72 | 1.75% | 0.27 |
LENZ closed up 1.75 percent on Friday, April 26, 2024, on 2.17 times normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Bullish Engulfing | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Strong but Oversold | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Strong, Oversold and Reversal Signs | Reversal | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Strong but Oversold | Other | 1.75% | |
| Wide Bands | Range Expansion | 1.75% |
| Alert | Time |
|---|---|
| Up 3% | about 13 hours ago |
| Possible Pocket Pivot | about 13 hours ago |
| Possible NR7 | about 13 hours ago |
| Up 2% | about 14 hours ago |
| 3x Volume Pace | about 15 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/18/2024
LENZ is a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase 3 CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for "all eyes, all day." LENZ is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Presbyopia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Presbyopia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.59 |
| 52 Week Low | 6.6976 |
| Average Volume | 92,361 |
| 200-Day Moving Average | 10.05 |
| 50-Day Moving Average | 15.28 |
| 20-Day Moving Average | 19.00 |
| 10-Day Moving Average | 17.04 |
| Average True Range | 1.47 |
| RSI (14) | 35.06 |
| ADX | 38.4 |
| +DI | 23.37 |
| -DI | 22.56 |
| Chandelier Exit (Long, 3 ATRs) | 20.17 |
| Chandelier Exit (Short, 3 ATRs) | 19.55 |
| Upper Bollinger Bands | 23.68 |
| Lower Bollinger Band | 14.33 |
| Percent B (%b) | 0.15 |
| BandWidth | 49.25 |
| MACD Line | -0.13 |
| MACD Signal Line | 0.69 |
| MACD Histogram | -0.819 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.03 | ||||
| Resistance 3 (R3) | 16.98 | 16.49 | 16.81 | ||
| Resistance 2 (R2) | 16.49 | 16.16 | 16.52 | 16.74 | |
| Resistance 1 (R1) | 16.11 | 15.95 | 16.30 | 16.16 | 16.67 |
| Pivot Point | 15.62 | 15.62 | 15.71 | 15.64 | 15.62 |
| Support 1 (S1) | 15.23 | 15.28 | 15.42 | 15.28 | 14.77 |
| Support 2 (S2) | 14.74 | 15.07 | 14.77 | 14.70 | |
| Support 3 (S3) | 14.36 | 14.74 | 14.63 | ||
| Support 4 (S4) | 14.41 |
